Inspire Medical Gains Momentum in US & Abroad During Q1
One key factor driving Inspire's growth achieved during Q1 was the performance of the company's Advisor Care Program.
Category: Neurostimulators
Neurostimulators
Latest
Neurostimulators
LatestInspire Medical Saw Sleep Apnea Device Sales Soar During 2021
Inspire Medical announced Tuesday that its 2021 revenue would be between $233 million and $233.4 million, a robust increase of about 102% over the previous year.
Neurostimulators
Latest
5-Year Study Confirms Safety, Efficacy, Beneficial Effects of Remedē System
The data show sustained improvements from baseline that were highly consistent with the previously published 6-, 12-, 24-, and 36-month results.
Signifier Raises $35M to Accelerate Commercialization of eXciteOSA Therapy
Proceeds of the financing will be directed towards commercialization of eXciteOSA in core target markets, continued development of proprietary digital patient and physician interface platforms, the generation of additional clinical data to reinforce the therapeutic efficacy of eXciteOSA, and progressing reimbursement.
Read MoreFDA Gives LivaNova Approval for Aura6000 Clinical Study for Obstructive Sleep Apnea
This randomized controlled trial will take place at approximately 20 sites across the United States and will enroll a maximum of 150 adult patients with moderate to severe OSA who do not achieve results from a traditional CPAP machine or have declined its use.
Read More
Scientists Observe Vagus Nerve Stimulation Effect on Brain Activity During Sleep & Wakefulness
Vagal-evoked potentials were largest during a specific sleep stage called nonREM sleep, during which large, slow waves dominate the electrical activity of the brain.
Read More
How to Make Neurostimulator Acclimatization Easier for Patients
Many patients give up on CPAP because they can’t tolerate the machine. Implanted neurostimulators may help, but, like positive airway pressure, these new devices can take some getting used to.
Read MoreNyxoah Neurostimulator Trial Reaches Its Primary Endpoints
The trial includes a subgroup of complete concentric collapse patients who are currently contraindicated for unilateral hypoglossal nerve stimulation.
Read MoreAnthem Issues Positive Coverage Policy for Inspire Therapy
This positive coverage decision provides additional OSA patients who are unable to benefit from CPAP the opportunity to gain access to Inspire therapy.”
Read More
New Distribution Agreement to Commercialize Inspire Therapy in Japan
Inspire and Japan Lifeline Co Ltd worked closely with the Minister of Health Labour and Welfare to advance the reimbursement application for Inspire therapy, which was approved by an expert panel this month.
Read More
ZOLL Medical Acquires Respicardia
ZOLL, which has been a significant investor in Respicardia for more than 3 years, will welcome all Respicardia employees into its workforce.
Read More
Signifier’s Daytime OSA Therapy Wins 2020 GOOD DESIGN Award
The GOOD DESIGN award is presented by The Chicago Athenaeum Museum of Architecture and Design and The European Centre for Architecture Art Design and Urban Studies.
Read More
Patient with Complete Concentric Airway Collapse Achieves Control of Sleep Apnea in Nyxoah Neurostimulator Study
Currently, patients with complete concentric collapse are contraindicated for hypoglossal nerve stimulation OSA therapies.
Read More
Tampa General Becomes One of Select Hospitals to Offer Respicardia Remedē for Central Sleep Apnea
The Respicardia remedē system is an implantable pacemaker-like battery pack that stimulates the phrenic nerve.
Read MoreFDA: Patients with Nyxoah Implant OK to Undergo MRI
This revised labeling ensures that patients who receive the Genio system and those already implanted can now undergo full-body 1.5T and 3T MRI diagnostic scans within approved parameters.
Read More
Nyxoah Partners with Vanderbilt to Develop More Neurostimulation Tech for OSA
The agreement allows Nyxoah to further develop new neurostimulation technologies for the treatment of sleep-disordered breathing conditions that were invented by Vanderbilt’s David T. Kent, MD.
Read MoreEuropean Union: Patients with Nyxoah Implant OK to Undergo MRI
‘Those who may need an MRI can benefit from Nyxoah’s innovations with no fear for themselves and their implant during the exam.’
Read MoreMultidisciplinary Perspectives on OSA Treatment with Inspire for CPAP-intolerant Patients
Panelists discuss proper patient selection, preparation for device evaluation and the procedure, and post-implant adjustments.
Read More